Astorg Adds Two Senior Hires to Investment Team
Pan-European private equity firm Astorg has added Chris Benson as a Partner and Daniel Pang as a Managing Director.
Benson will join the firm in early July as a Partner for the Mid-Cap Fund, leading the Business Services sector across Europe and having responsibility for coverage in the UK. Pang joins the Healthcare team as a Managing Director for the Flagship Fund.
Consistent with the firm’s strategy and expertise, Astorg’s Mid-Cap fund seeks to invest in Europe-based, international B2B niche leaders that benefit from secular and
“We are delighted to welcome Chris to the team. His deep industry knowledge and network, as well as his investment track-record, will be very additive to our team as we continue to strengthen our focus on business services across Europe. Astorg has already built a strong track-record in the sector, and we see great investment opportunities ahead in the middle market. Chris’ personality and experience fit very well with Astorg’s entrepreneurial and thematic approach to investing, and we look forward to working with him," said Lionel de Posson and Edouard Pillot, Co-Heads of Astorg Mid-Cap.
Daniel has a wealth of experience identifying and building value across many sub-sectors of the healthcare industry and we are pleased to have him on board. His expertise will be a great asset as we continue to capitalise on the vast opportunities within the healthcare sector and deliver on our mission to build global B2B niche leaders in the space," said Judith Charpentier, Head of Healthcare and Co-Head of Flagship Fund.
Benson previously spent 12 years at Advent International focused on European business and financial services. His background also includes roles at Actis and OC&C Strategy Consultants. Pang was previously a Principal in the healthcare group at Welsh, Carson, Anderson and Stowe. Prior to that, he has also held positions at Arsenal Capital Partners and GTCR, specialising in building healthcare businesses.
© The Sortino Group Ltd
All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency or other Reprographic Rights Organisation, without the written permission of the publisher. For more information about reprints from AlphaWeek, click here.
